Please login to the form below

Skyrizi

This page shows the latest Skyrizi news and features for those working in and with pharma, biotech and healthcare.

AbbVie/Allergan merger faces renewed public opposition despite divestments

AbbVie. They also highlighted AbbVie’s use of controversial “rebate walls” around its blockbuster immunology products – including Humira and Skyrizi – which the groups say “lead to higher prescription drug prices” and

Latest news

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well ... IL-23 antagonist Skyrizi for psoriasis did particularly
Cosentyx, Entresto drive topline growth for Novartis in Q4

However, in head-to-head trials with both AbbVie’s Humira (adalimumab) and Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Skyrizi also met a non-inferiority endpoint at 16 weeks, with 74% of patients achieving PASI 90 versus 66% for Cosentyx. ... Skyrizi meanwhile only needs to be dosed every 12 weeks after an initial loading phase.
AbbVie creates new aesthetics division amid Allergan takeover

This includes psoriasis treatment Skyrizi, Rinvoq, medical Botox, and cancer treatments Imbruvica and Veclexta.
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis.

More from news
Approximately 8 fully matching, plus 17 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Developed by Boehringer Ingelheim and AbbVie, Skyrizi is a monoclonal antibody that inhibits the pro-inflammatory cytokine IL-23. ... Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...